Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Research & Development (2016 - 2025)

Historic Research & Development for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $56.1 million.

  • Regenxbio's Research & Development rose 307.19% to $56.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.1 million, marking a year-over-year increase of 245.3%. This contributed to the annual value of $208.5 million for FY2024, which is 1022.28% down from last year.
  • Latest data reveals that Regenxbio reported Research & Development of $56.1 million as of Q3 2025, which was up 307.19% from $59.5 million recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Research & Development peaked at $63.3 million during Q3 2022, and registered a low of $39.7 million during Q1 2021.
  • Over the past 5 years, Regenxbio's median Research & Development value was $55.6 million (recorded in 2022), while the average stood at $54.4 million.
  • Per our database at Business Quant, Regenxbio's Research & Development skyrocketed by 4004.08% in 2022 and then tumbled by 1839.66% in 2024.
  • Over the past 5 years, Regenxbio's Research & Development (Quarter) stood at $48.0 million in 2021, then soared by 30.28% to $62.5 million in 2022, then decreased by 10.92% to $55.7 million in 2023, then dropped by 9.52% to $50.4 million in 2024, then increased by 11.36% to $56.1 million in 2025.
  • Its Research & Development was $56.1 million in Q3 2025, compared to $59.5 million in Q2 2025 and $53.1 million in Q1 2025.